{"prompt": "['2', 'INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE', '2.1', 'Background Information', 'Bipolar Disorder is a serious psychiatric disorder associated with shifts in mood', 'including manic or hypomanic episodes, depressed episodes, or mixed episodes.', 'Bipolar I Disorder is defined by the presence of manic or mixed episodes, whereas', 'Bipolar II Disorder is defined by hypomania, but both are often associated with major', 'depressive episodes. Bipolar Disorder affects approximately 5.7 million adult', 'Americans, or about 2.6% of the U.S. population age 18 and older, every year', 'according to the National Institute of Mental Health with similar prevalence worldwide.', 'Depressive episodes associated with Bipolar Disorder tend to last longer, recur more', 'often, and are associated with worse prognosis than manic/hypomanic episodes.', 'Bipolar Depression, the predominant presentation of Bipolar Disorder, remains a', 'significantly underserved medical need, with only a few regulatory-approved treatment', 'options available.', 'Intra-Cellular Therapies (ITI) is developing lumateperone (ITI-007), a new chemical', 'entity, for the treatment of patients with schizophrenia, major depressive episodes', '(MDEs) associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) and for the', \"treatment of agitation associated with dementia, including Alzheimer's disease.\", 'ITI-007 is a novel small molecule therapeutic agent designed specifically to combine', 'serotonergic, dopaminergic and glutamatergic modulation in a dose-dependent manner.', 'ITI-007 is a potent serotonin 5-HT2A receptor antagonist with mesolimbic/mesocortica', 'selective modulation of phosphoprotein pathways downstream of dopamine receptors,', 'serotonin reuptake inhibition, and indirect glutamatergic modulation (Snyder et al 2015).', 'As a dopamine receptor protein phosphorylation modulator, ITI-007 has dual properties,', 'acting as post-synaptic antagonist and as a pre-synaptic partial agonist at dopamine 2', '(D2) receptors in vivo, with mesolimbic/mesocortical selectivity. ITI-007 also increases', 'the phosphorylation of the NR2B, or GluN2B, subunit of N-methyl-D-aspartate channels', 'in extrastriatal dopamine-rich brain regions (e.g., nucleus accumbens) and indirectly', 'modulates glutamatergic (NDMA and AMPA) activity downstream from dopamine 1', 'receptor activation.', 'Evidence supports the use of D2 receptor antagonists in the treatment of Bipolar', 'Disorder, including Bipolar Depression (Young et al 2013; Loebel et al 2014a, 2014b),', 'as both monotherapy and adjunctive therapy to mood stabilizers. The pharmacologic', 'profile of ITI-007 includes both the post-synaptic D2 antagonism that appears efficacious', 'in Bipolar Disorder and other pharmacological properties that may confer better safety', 'Intra-Cellular Therapies, Inc. Confidential', '2 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['and tolerability than other D2 antagonists. As a 5-HT2A receptor antagonist and', 'serotonin reuptake inhibitor, ITI-007 is predicted to have antidepressant efficacy with', 'fewer side effects than selective serotonin reuptake inhibitors (Meltzer et al 1989). ITI-', \"007's indirect glutamatergic modulation in combination with serotonin reuptake inhibition\", 'predicts rapid-acting antidepressant response. Importantly, ITI-007 lacks potent off-', 'target interactions that have been associated with side effects for other antipsychotics', 'drugs approved for the treatment of Bipolar Depression. For example, ITI-007 shows', 'relatively weak affinity for 5-HT2c and no measurable affinity for H1 or muscarinic', 'cholinergic receptors, which predict favorable body weight and metabolic profile', 'responses to the extent that these receptors mediate such effects. Additional details on', \"the pharmacologic profile of ITI-007 can be found in the Investigator's Brochure.\", 'Nonclinical data suggest that ITI-007 may have the potential to treat depression (Snyder', 'et al 2015). Antidepressant-like activity of ITI-007 was measured using the social defeat', '(resident-intruder) mouse model. Mice exposed to repeated social defeat conditions', 'display a reduced amount of time in contact with unfamiliar non-aggressive mice than', 'normal controls. Such defeat behavior is reversed by chronic (but not acute) treatment', 'with clinically effective antidepressant drugs. In this model, 1 m/kg ITI-007,', 'administered once daily intraperitoneally for 28 days, reversed the defeat behavior,', 'consistent with antidepressant efficacy. Brain receptor target engagement was', 'confirmed in healthy male volunteers in the ITI-007-003 positron emission tomography', '(PET) Phase 1 clinical trial (Davis et al 2015). Positron emission tomography was used', 'to determine dopamine D2 receptor, serotonin transporter (SERT), and serotonin 5-HT2A', 'receptor occupancy in the brain at various times following single dose oral ITI-007', 'administration. ITI-007 rapidly penetrated the brain, showed long-lasting and dose-', 'related occupancy, and was generally safe and well-tolerated. Cortical 5-HT2A receptors', 'were shown to be fully occupied at 10 mg ITI-007 (>85% occupancy). A dose of 40 mg', 'ITI-007 achieved up to 39% striatal D2 occupancy (average of 29%) and up to 31%', 'striatal SERT occupancy (average of 22%). Together, these data confirm a central', 'mechanism for ITI-007 at dopaminergic and serotonergic brain targets. An additional', 'PET study in patients with schizophrenia (ITI-007-008) demonstrated an average of', 'approximately 40% striatal D2 receptor occupancy at 60 mg, at plasma steady state,', 'lower than that observed with most antipsychotic drugs. Relatively low striatal D2', 'receptor occupancy likely contributes to a relatively low liability for extrapyramidal side', 'effects and hyperprolactinemia compared to most antipsychotic drugs.', 'Clinical data from three well-controlled studies in patient with schizophrenia (ITI-007-', '005, ITI-007-301, and ITI-007-302) are consistent with respect to the pharmacological', 'profile and prediction for antidepressant effects with favorable safety and tolerability. In', 'these three studies ITI-007 has been safely administered once daily for up to 42 days at', 'Intra-Cellular Therapies, Inc. Confidential', '3 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}